IDH1 and acute myeloid leukemia: A phase 3 randomized study of ivosidenib with intensive chemotherapy in newly diagnosed IDH1-mutated AML is currently underway (NCT03839771) It is important to note that given the design of this study, which plans to add ivosidenib to induction, consolidation, and as a maintenance therapy, it may be challenging to understand the relative impact of ivosidenib treatment within each treatment stage.